海思科：子公司获得《药物临床试验批准通知书》

Core Viewpoint - Haikang Pharmaceutical Group Co., Ltd. announced that its subsidiary, Shanghai Haikang Shennuo Pharmaceutical Technology Co., Ltd., received approval from the National Medical Products Administration for clinical trials of four new chemical drugs, indicating progress in its drug development pipeline [1] Company Summary - Haikang's subsidiary has received a clinical trial approval for HSK45019 tablets, HSK50042 tablets, injectable HSK55718, and HSK36357 capsules, which are classified as Class 1 chemical drugs [1] - The company's revenue composition for the first half of 2025 shows that the pharmaceutical industry accounts for 99.14% of total revenue, while other businesses contribute 0.86% [1] - As of the report date, Haikang's market capitalization stands at 58.4 billion yuan [1]